Latest news

• Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

  It combines ViiV’s own Tivicay (dolutegravir) the most widely prescribed integrase inhibitor worldwide, and J&J’s  Edurant (rilpivirine).

• ViiV’s two-drug HIV combo backed by CHMP

  The advisory committee issued a positive opinion for Juluca - which combines ViiV’s integrase inhibitor Tivicay (dolutegravir) with a non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine) developed by Johnson &Johnson’s

• GSK’s ViiV gets US okay for two-drug HIV regimen

  GSK’ s ViiV gets US okay for two-drug HIV regimen. Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant. ... The US regulator gave a green light to Juluca, which combines ViiV’s integrase inhibitor Tivicay (dolutegravir) with a

• ViiV files two-drug HIV maintenance regimen

  inhibitor Edurant (rilpivirine) in the US and EU.

• Gilead gets EU nod for TAF-based triple therapy for HIV

  The once-daily, single-tablet combines TAF with emtricitabine - a dual therapy sold as Descovy - with Johnson &Johnson's Edurant (rilpivirine).